GlassScriptPhysician profile
Saira Samani
NPI 1841517653
$2,973.13
in general payments reported to CMS, 2019-2025
20 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $476 · 2021: $202 · 2022: $186 · 2023: $609 · 2024: $738 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $448.54 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $362.44 | 2023-2025 | Avvigo Guidance System, General - Balloon Catheters |
| Abbott Laboratories | $347.61 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx |
| Bard Peripheral Vascular, INC. | $295.02 | 2020-2022 | |
| Abiomed | $248.25 | 2024-2025 | Impella |
| Inari Medical, INC. | $216.38 | 2020-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $166.78 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $146.14 | 2022-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $130.85 | 2023-2024 | Micra, Venaseal |
| Cardiovascular Systems INC. | $128.73 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.65 | 2020 | |
| Cardinal Health 200 LLC | $91.79 | 2019 | |
| Pfizer INC. | $53.66 | 2024 | |
| Chiesi USA, INC. | $51.16 | 2019 | |
| Philips North America LLC | $42.17 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40.73 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $33.97 | 2023-2024 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $26.44 | 2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $23.36 | 2020 | |
| Cvrx, INC. | $21.46 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saira Samani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.